



Press release |

Regulated information

IBA STRENGTHENS MANAGEMENT TEAM FOR FUTURE GROWTH

- Jean-Marc Bothy to assume new role of Chief Strategy Officer
- Soumya Chandramouli appointed as Chief Financial Officer

Louvain-La-Neuve, Belgium, 2 June 2016 - IBA (Ion Beam Applications S.A., Euronext), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces the strengthening of its management team with the promotion of Jean-Marc Bothy to Chief Strategy Officer and the appointment of Soumya Chandramouli as Chief Financial Officer.

As Chief Strategy Officer Jean-Marc will be primarily responsible for the Company's key partnerships, which are an essential part of the Company's strategy. The role will also encompass review of further growth expansion opportunities. With support from Soumya, Jean-Marc will retain the investor relations and corporate communications functions as part of his role.

Soumya Chandramouli joined IBA from EY in 2004 and, over this period, she has taken on increasing responsibility within IBA's finance department, most recently as VP Finance for the Proton Therapy and Other Accelerators division. She holds a Master in Business from the University of Liège and a degree from the Belgian Association of Financial Analysts (ABAF).

Olivier Legrain, Chief Executive Officer of IBA commented: *"The proton therapy market is growing at an unprecedented rate as the support for the technology grows, costs come down and clinicians recognise the importance of this treatment modality. IBA is at the centre of this growth and with record backlogs and workforce expansion, these management team appointments further bolster our ability to capitalise on the many exciting opportunities facing the Company and further establish our leadership of this market."*

"Jean-Marc has been with IBA for more than 15 years and I am extremely pleased that he will now focus his time on continuing to execute on the Company's strategic direction. Similarly, after 12 years with us, Soumya is a great addition to the management team and I look forward to working with her more closely in her new role."

Ends

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.



Press release |

Regulated information

Headquartered in Belgium and employing about 1,300 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

For further information please contact:

IBA

Jean-Marc Bothy
Chief Strategy Officer
+32 10 475 890

Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700

IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+1 917 322 2571

mcarey@RxIR.com